Merrion Pharmaceuticals Plc Signs Collaboration and Option Agreement and Warrant Agreement With Novo Nordisk
22 déc. 2010 02h00 HE
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the signing of a Collaboration and Option agreement with...
Merrion Pharmaceuticals Plc Signs Feasibility and Option Agreement for 3 Drugs With International 'Top Ten' Pharmaceutical Company
06 déc. 2010 02h00 HE
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, Dec. 6, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and...
Merrion Pharmaceuticals Plc Announces Commencement of Feasibility and Option Agreement With Rebel Pharmaceuticals
23 nov. 2010 09h00 HE
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, Nov. 23, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery feasibility and...
Merrion Finalises Its Phase III Development Program for Orazol(TM) in the USA
16 nov. 2010 02h00 HE
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, Nov. 16, 2010 (GLOBE NEWSWIRE) -- After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol™. If successful, the Phase III...
Merrion Pharmaceuticals is Issued a Key U.S. Patent for Orazol(TM), Their Lead Product to Treat Bone Metastases Associated With Prostate, Breast and Other Cancers
07 mai 2010 03h00 HE
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, May 7, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals plc (IEX:MERR), a pharmaceutical development company, today announces that it has been granted a further U.S. Patent,...
Merrion Pharmaceuticals is Issued a Key United States Patent
02 mars 2010 02h00 HE
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, March 2, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals plc (IEX:MERR), an international specialty pharmaceutical company, today announced the issuance of United States Patent No....
Novo Nordisk Starts Phase 1 Trial With Oral Insulin Analogue -- Merrion Pharmaceuticals Earns USD 2 Million Milestone Payment
07 déc. 2009 06h30 HE
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, Dec. 7, 2009 (GLOBE NEWSWIRE) -- Novo Nordisk today announced that it has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a...
Merrion Pharmaceuticals Plc gibt erste Ergebnisse der Phase II Orazol(tm) Studie bekannt
20 mai 2009 09h19 HE
|
Merrion Pharmaceuticals plc
DUBLIN, Irland, 15. Mai 2009 (GLOBE NEWSWIRE) - Dr. John Fox von Merrion
Pharmaceuticals („Merrion“ oder das Unternehmen) wendet sich heute an die 7.
Internationale Krebskonferenz in Dublin und wird...
Merrion Pharmaceuticals Plc annuncia i risultati preliminari sullo studio in Fase II per Orazol(tm)
20 mai 2009 09h19 HE
|
Merrion Pharmaceuticals plc
DUBLINO, Irlanda, 15 maggio 2009 (GLOBE NEWSWIRE) - Il dott. John Fox, di
Merrion Pharmaceuticals ("Merrion" o la "Societa"), oggi parteciperà alla 7th
International Cancer Conference a Dublino ed...
Merrion Pharmaceuticals Plc anuncia resultados preliminares en el estudio en fase II de Orazol(tm)
20 mai 2009 09h19 HE
|
Merrion Pharmaceuticals plc
DUBLIN, Irlanda, 15 de mayo, 2009 (GLOBE NEWSWIRE) -- El doctor John Fox, de
Merrion Pharmaceuticals ("Merrion" o la "Compañía"), dirigirá hoy la séptima
Conferencia Internacional del Cáncer en...